Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
Morphic Therapeutic (Nasdaq: MORF) announced that its President and CEO, Praveen Tipirneni, M.D., will participate in a virtual panel on gastrointestinal and microbiome topics at the 42nd Annual Cowen Healthcare Conference on March 9th at 10:30 AM ET. The event will be accessible via live webcast on the company's investor website, with a replay available afterward. Morphic is focused on developing oral integrin therapies for serious chronic diseases, partnering with AbbVie, Janssen, and Schrödinger, and utilizing its proprietary MInT technology platform.
- Participation in a prominent healthcare conference enhances visibility.
- Collaboration with established companies like AbbVie and Janssen supports credibility.
- Focus on developing therapies for serious chronic diseases indicates strong market potential.
- None.
WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic President and CEO Praveen Tipirneni, M.D. will participate in a gastrointestinal and microbiome virtual panel discussion at the 42nd Annual Cowen Healthcare Conference at 10:30 AM ET on Wednesday, March 9th.
A live webcast of the event will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
FAQ
What event will Morphic Therapeutic's CEO participate in?
What is the focus of Morphic Therapeutic's development efforts?
Where can I watch the live webcast of the Morphic Therapeutic panel discussion?
When will the replay of the Morphic Therapeutic panel discussion be available?